Pharmacogenetics for Pain Management in Joint Replacement Patients

Phase 3

• Conditions: Arthroplasty Complications
• Interventions: Diagnostic Test: Pharmacogenomics Testing

• Registration Number: NCT03772535
• Lead Sponsor: Anderson Orthopaedic Research Institute

Brief Summary

The purpose of this study is to determine the ability to use pharmacogenetic testing in a joint replacement practice to prescribe the most effective pain medicine for a specific patient.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-12-03
• Study First Submitted: 2018-12-10
• Study First Submitted QC: 2018-12-10
• Study First Posted: 2018-12-11
• Status Verified: 2021-02
• Last Update Submitted: 2021-02-10
• Last Update Posted: 2021-02-12
• Primary Completion: 2021-06
• Study Completion: 2021-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Primary total hip or total knee arthroplasty cases

Exclusion Criteria

• History of narcotic dependence

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Pharmacogenomics Guided Group	Pharmacogenomics Testing	Subjects in this group will receive postoperative pain prescriptions based on the results of pharmacogenomic testing.

Primary Outcome Measures

Name	Time	Method
Genetic variants	10 days postoperative	Percent of subject with genetic variants affecting pain medication

Secondary Outcome Measures

Name	Time	Method
pain levels	10 days postoperatively	0-10 subjective pain scale

Trial Locations

Locations (1)

Anderson Orthopaedic Research Institute; 🇺🇸 Alexandria, Virginia, United States